SIMVASTATIN

Visit The Healthy Living Bookshelf:

21 Online Health Books From Rodale

Safetychecker Summary for Simvastatin
(for details about the summarized interactions, read the full article)

May be Beneficial: Depletion or interference—The medication may deplete or interfere with the absorption or function of the nutrient. Taking these nutrients may help replenish them.	Coenzyme Q10
May be Beneficial: Supportive interaction—Taking these supplements may support or otherwise help your medication work better.	Fish oil (EPA) Vitamin E*
Avoid: Adverse interaction—Avoid these supplements when taking this medication because taking them together may cause undesirable or dangerous results.	Vitamin A*
Check: Other—Before taking any of these supplements or eating any of these foods with your medication, read this article in full for details.	Niacin
Side effect reduction/prevention	None known
Reduced drug absorption/bioavailability	None known

Interactions with Dietary Supplements

Coenzyme Q10
In patients with high cholesterol, simvastatin therapy results in decreased serum coenzyme Q10 (CoQ10) levels.^{1 2} Several trials, including double-blind trials, have confirmed this effect of simvastatin and other HMG-CoA reductase inhibitors, such as lovastatin and pravastatin.^{3 4 5} Supplementation with 100 mg⁶ per day or 10 mg three times daily⁷ of CoQ10 has been shown to prevent reductions in blood levels of CoQ10 due to simvastatin. In the latter study, people taking CoQ10 along with simvastatin increased their blood CoQ10 concentration by 63%. Many doctors recommend that people taking HMG-CoA reductase inhibitor drugs such as simvastatin also supplement with approximately 100 mg CoQ10 per day, although lower amounts, such as 10–30 mg per day might conceivably be effective in preventing the decline in CoQ10 levels.

The omega-3 fatty acid EPA, present in fish oil, may improve the cholesterol and triglyceride-lowering effect of simvastatin. In a preliminary trial, people with high cholesterol who had been taking simvastatin for about three years were able to significantly lower their triglyceride levels and raise their levels of HDL (“good”) cholesterol by supplementing with either 900 mg or 1800 mg of EPA for three months in addition to simvastatin.⁸ The authors of the study concluded that the combination of simvastatin and EPA may prevent coronary heart disease better than simvastatin alone.

Niacin
Niacin is the form of vitamin B3 used to lower cholesterol. High-dose niacin taken with lovastatin (a drug closely related to simvastatin) or with simvastatin itself may cause muscle disorders (myopathy) that can become serious (rhabdomyolysis).^{9 10} Such problems appear to be uncommon.^{11 12} Moreover, niacin has been successfully combined with statin drugs to reduce cholesterol more effectively than using these drugs without niacin.^{13 14} People taking both simvastatin and niacin should be monitored for muscle disorders by the prescribing physician.

Vitamin A
A study of 37 people with high cholesterol treated with diet and HMG-CoA reductase inhibitors found blood vitamin A levels increased over two years of therapy.¹⁵ Until more is known, people taking HMG-CoA reductase inhibitors, including simvastatin, should have blood levels of vitamin A monitored if they intend to supplement vitamin A.

Vitamin E
In a study of seven patients with hypercholesterolemia, eight weeks of simvastatin plus vitamin E 300 IU improved markers of blood vessel elasticity more than simvastatin alone.¹⁶

Interactions with Foods and Other Compounds

Food
Simvastatin may be taken with or without food.¹⁷

1. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62–6.

2. Laaksonen R, Ojala JP, Tikkanen MJ, et al. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313–7.

3. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226–9.

4. Watts GF, Cummings MH, Umpleby M, et al. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995;25:559–67.

5. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931–4.

6. Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Molec Aspects Med 1994;15(suppl):s187–93.

7. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999;49:324–9.

8. Nakamura N, Hamazaki T, Ohta M, et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res 1999;29:22–5.

9. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995;52:1639–45.

10. Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Parmacother 1998;32:1030–43.

11. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol 1994;73:25D–9D.

12. Jokubaitis LA. Fluvastatin in combination with other lipid-lowering agents. Br J Pract Suppl 1996;77A:28–32.

13. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, Nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994;73:339–45.

14. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994;96(suppl 6A):64S–8S.

15. Muggeo M, Zenti MG, Travia D, et al. Serum retinol levels throughout 2 years of cholesterol-lowering therapy. Metabolism 1995;44:398–403.

16. Neunteufl T, Kostner K, Katzenschlager R, et al. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol 1998;32:711–6.

17. Threlkeld DS, ed. Diuretics and Cardiovasculars, Antihyperlipidemic Agents, HMG-CoA Reductase Inhibitors. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, Sep 1998, 172.

---

Copyright © 2002 Healthnotes, Inc.  All rights reserved. www.healthnotes.com

Please read the disclaimer about the limitations of the information provided here. Do NOT rely solely on the information in this article.

Learn more about Healthnotes, the company.

Learn more about the authors of Safetychecker.

The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2003.

---

• Ways to Shop
• Track Your Orders
• Quick Re-order

• Shipping Costs & Times
• Return Policy
• International Shipping - New!

• Help Desk
• Contact Us

• Join our Affiliate Network
• Corporate Discounts
• Gift Certificates